VANCOUVER, BRITISH COLUMBIA--(MARKET WIRE)--Sep 19, 2007 -- Chemokine Therapeutics Corp. (the “Company”) (Toronto:CTI.TO - News)(OTC BB:CHKT.OB - News), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, announced that an abstract, entitled “Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers”, submitted by the Investigators has been accepted by the American Association for Cancer Research (“AACR”) for presentation at the Molecular Targets and Cancer Therapeutics International Conference being held in San Francisco, California on October 22-26, 2007. The abstract will be presented by Dr. Sebastien Hotte, Assistant Professor, Department of Oncology, McMaster University and Medical Oncologist and Head, Phase I Programme, Juravinski Cancer Centre.
